Abstract: A biological production system includes a mixing vessel and an agitation device. The mixing vessel includes an outer housing, an internal mixing structure, and a reaction chamber. The mixing vessel is configured to provide low shear agitation to materials in the reaction chamber in response to force from the agitation device.

Abstract: The present invention provides for a topical composition that includes a topical carrier and an adenosine deaminase inhibitor. Suitable specific adenosine deaminase inhibitors include, e.g., deoxycoformycin (dCF), deoxyadenosine (dAdo), cladrabine (CdA), fludarabine (F-Ara-A), cytrabine (Ara-C), and thioguanine. The present invention also provides for a method to treat lymphocyte mediated skin diseases and to alleviate symptoms associated with such skin diseases. The method includes topically administering the composition to a mammal in need of such treatment. The present invention also provides for kits and syringe systems that include the adenosine deaminase inhibitor.

Abstract: A process for lyophilizing a solution of an active agent in a container is provided. Solution of active agent is deposited into a container, the container is covered with a covering plate and placed inside a lyophilizing apparatus. Lyophilization can be conducted to dryness by radiation, convection or both. Also provided is a device made by this process, an active agent-plastic administration device (e.g., a syringe), containing an active agent in the form of lyophilized cake, and an array of such administration devices.

Abstract: This invention relates to reduced stinging, sustained release ophthalmic formulations and the method of treatment comprising administering such formulations topically to the eye when in need thereof.

Abstract: A pharmaceutical product comprising an aqueous prostaglandin formulation and a polypropylene container are disclosed. Aqueous prostaglandin formulations are more stable in polypropylene containers than polyethylene containers.